Erica Barnell, MD, PhD

GI Oncology Now

<p>Erica Barnell, MD, PhD, of Washington University School of Medicine, and founder of Geneoscopy Inc, talks about the recent inclusion of ColoSense, a multitarget stool RNA test, in the National Comprehensive Cancer Network (NCCN) Guidelines for colorectal cancer screening.<p>Dr. Barnell highlights how the inclusion of this technology reduces disparities in colorectal cancer screening, how clinicians can integrate ColoSense in their clinic, and more.</p></p>


Emily Menendez

Gemcitabine Plus Cisplatin Boosts OS, Resection Rates for Biliary Tract Cancer

Bile Duct Cancer

ColoSense Included in NCCN Guidelines for Colorectal Cancer Screening

Colorectal Cancer

Aiwu (Ruth) He, PhD

Immunotherapy in HCC: Navigating Combinations, Patient Selection, and Evolving Opportunities

Liver Cancer

Latest News

Dr. Barnell discusses ColoSense's NCCN Guidelines inclusion for CRC and how it impacts the cancer screening landscape. 

ColoSense Included in NCCN Guidelines for CRC Screening

About Us

Editorial Policy

Advertising

eNewsletters

Contribute

GU Oncology Now

Lung Cancers Today

Cancer Nursing Today

DocWire News

MashupMD

Bile Duct

Colorectal

Esophageal

Gastric

GEP-NETs

GIST

Liver

Pancreatic

Conference Coverage

Video Insights

Roundtable